MADRIGAL PHARMACEUTICALS, INC.(MDGL)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

MADRIGAL PHARMACEUTICALS, INC. (MDGL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores MDGL at 40.7/100 on a 32-signal composite quality model, placing it at rank #2,092 of 2,960 stocks — the bottom half of the AI-ranked universe. MDGL scores in the top quartile across revenue growth (99.3). Areas of concern include balance sheet strength (8.2) and free cash flow (14.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), MADRIGAL PHARMACEUTICALS, INC. reports quarterly revenue of $364.3M, net income of $-57.9M, free cash flow of $19.1M. Top institutional holders of MDGL by reported 13-F value include BAKER BROS. ADVISORS, RTW INVESTMENTS, Jupiter Topco, based on the most recent SEC filings. MDGL trades on the Nasdaq exchange and files with the SEC under CIK 1157601. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MDGL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for MADRIGAL PHARMACEUTICALS, INC. directly from SEC EDGAR.